Journal
JOURNAL OF PHARMACY AND PHARMACOLOGY
Volume 63, Issue 4, Pages 550-557Publisher
WILEY
DOI: 10.1111/j.2042-7158.2010.01238.x
Keywords
antagonist; cysteinyl leukotriene receptor 1; focal cerebral ischaemia; montelukast; neuroprotection
Categories
Funding
- National Natural Science Foundation [30672449, 30772561]
Ask authors/readers for more resources
Objectives Previously we demonstrated the neuroprotective effect of montelukast, a cysteinyl leukotriene receptor-1 (CysLT(1)) antagonist, on acute brain injury after focal cerebral ischaemia in mice. In this study, we have determined its effect on chronic brain injury after focal cerebral ischaemia in mice and rats. Methods After transient focal cerebral ischaemia was induced by middle cerebral artery occlusion, montelukast was intraperitoneally injected in mice or orally administered to rats for five days. Behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss were determined to evaluate brain lesions. Key findings Montelukast (0.1 mg/kg) attenuated behavioural dysfunction, brain infarct volume, brain atrophy and neuron loss in mice, which was similar to pranlukast, another CysLT(1) receptor antagonist. Oral montelukast (0.5 mg/kg) was effective in rats and was more effective than edaravone, a free radical scavenger. Conclusion Montelukast protected mice and rats against chronic brain injury after focal cerebral ischaemia, supporting the therapeutic potential of CysLT(1) receptor antagonists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available